A Feasibility Study to Evaluate the Effect of Ustekinumab on Systemic and Vascular Inflammation Associated with Metabolic Syndrome and Cardiovascular Disease in Patients with Moderate to Severe Psoriasis using 18F-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography [18F-FDG PET/CT]

Trial Profile

A Feasibility Study to Evaluate the Effect of Ustekinumab on Systemic and Vascular Inflammation Associated with Metabolic Syndrome and Cardiovascular Disease in Patients with Moderate to Severe Psoriasis using 18F-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography [18F-FDG PET/CT]

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Mar 2018

At a glance

  • Drugs Ustekinumab (Primary)
  • Indications Psoriasis
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Mar 2018 According to results published in the Journal of the American Academy of Dermatology, patients and healthy individuals were referred and screened for the study between Mar 2013 and Feb 2015.
    • 17 Mar 2018 Results published in the Journal of the American Academy of Dermatology.
    • 08 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top